Arbutus Biopharma Corp is a biopharmaceutical company focused on developing treatments for chronic Hepatitis B virus (HBV) infection and other coronaviruses, including COVID-19. With a product pipeline that includes a subcutaneously-delivered RNAi therapeutic and an oral HBV RNA destabilizer, Arbutus aims to suppress HBV antigens and reawaken the immune system. The company, which was previously known as Tekmira Pharmaceuticals, collaborates with various pharmaceutical firms and is based in Warminster, Pennsylvania.
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many…
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Arbutus Biopharma shares jumped on Tuesday after the company reported positive data from its early-stage clinical trial in patients with chronic hepatitis B virus infection.
Chris Lange 
